RACHEL SWEENEY: Open Payments
NPI 1265424055 · ARNOLD, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$942 in 35 payments from 18 companies in 2025. Trend: 2023 $233 · 2024 $918 · 2025 $942
Food & beverage: $942
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $257 |
| Madrigal Pharmaceuticals | 1 | $108 |
| Medtronic, Inc. | 1 | $104 |
| Exact Sciences Corporation | 3 | $77 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $51 |
| ABBVIE INC. | 2 | $45 |
| Boston Scientific Corporation | 1 | $45 |
| Amgen Inc. | 2 | $40 |
| Abbott Laboratories | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
Products named: REZDIFFRA, Ozempic, SYMPLICITY G3, Wegovy, Rybelsus, The Cologuard Plus Collection Kit, XIFAXAN, WaveWriter Alpha Prime 16.
Industry payments across MD — which companies pay providers there.
